[
  {
    "ts": null,
    "headline": "Incyte Corp. stock outperforms competitors on strong trading day",
    "summary": "Incyte Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=5f0bc3f660022d66e2c7d25dd4b85534ebaa5f640c50429bd38585d35cba6596",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752513240,
      "headline": "Incyte Corp. stock outperforms competitors on strong trading day",
      "id": 135991757,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=5f0bc3f660022d66e2c7d25dd4b85534ebaa5f640c50429bd38585d35cba6596"
    }
  },
  {
    "ts": null,
    "headline": "India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement",
    "summary": "(Reuters) -India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp.  The company said 8 mg Leqselvi tablets for severe alopecia areata will be available in the U.S., after a launch delay caused by a patent infringement case in a U.S. court.  Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun's key U.S. market.",
    "url": "https://finnhub.io/api/news?id=05e3b50e6cd4629726644ca2ad0c91cd9c2eb140c560a9e5d85e16a50990beb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752493130,
      "headline": "India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement",
      "id": 135928446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "(Reuters) -India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp.  The company said 8 mg Leqselvi tablets for severe alopecia areata will be available in the U.S., after a launch delay caused by a patent infringement case in a U.S. court.  Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun's key U.S. market.",
      "url": "https://finnhub.io/api/news?id=05e3b50e6cd4629726644ca2ad0c91cd9c2eb140c560a9e5d85e16a50990beb7"
    }
  },
  {
    "ts": null,
    "headline": "India's Sun Pharma launches anti-baldness drug Leqselvi in US",
    "summary": "India's top drugmaker by revenue, Sun Pharma, on Monday launched its anti-baldness drug Leqselvi in the US market, following settlement of a patent dispute with Incyte Corp....",
    "url": "https://finnhub.io/api/news?id=19319163e5da275c29b653c87a6712effe64ebb27d27258aa5355b0169a2c793",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752478448,
      "headline": "India's Sun Pharma launches anti-baldness drug Leqselvi in US",
      "id": 135922696,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "India's top drugmaker by revenue, Sun Pharma, on Monday launched its anti-baldness drug Leqselvi in the US market, following settlement of a patent dispute with Incyte Corp....",
      "url": "https://finnhub.io/api/news?id=19319163e5da275c29b653c87a6712effe64ebb27d27258aa5355b0169a2c793"
    }
  }
]